Kanda T.Lau G.K.K.Wei L.Moriyama M.Yu M.-L.Chuang W.-L.Ibrahim A.Lesmana C.R.A.Sollano J.Kumar M.Jindal A.Sharma B.C.Hamid S.S.Dokmeci A.K.Mamun-Al-Mahtab, McCaughan G.W.McCaughan G.W.Mamun-Al-MahtabWasim J.Crawford D.H.G.JIA-HORNG KAOYokosuka O.Sarin S.K.Omata M.2021-09-042021-09-0420191936-0533https://www.scopus.com/inward/record.uri?eid=2-s2.0-85058543693&doi=10.1007%2fs12072-018-9915-5&partnerID=40&md5=c8d87fcd2b636f488875cf4faf062fc5https://scholars.lib.ntu.edu.tw/handle/123456789/581804Chronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12?weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir for 8–16?weeks also results in high SVR rates in patients with all HCV GTs and stage 4 or 5 CKD. However, these regimens are contraindicated in the presence of advanced decompensated cirrhosis. Although sofosbuvir and/or ribavirin are not generally recommended for HCV-infected patients with severe renal impairment, sofosbuvir-based regimens may be appropriate for those with mild renal impairment. To eliminate HCV worldwide, HCV-infected patients with renal impairment should be treated with interferon-free therapies. ? 2018, The Author(s).DAA; Guideline; HCV; Hemodialysis; Renal impairment; SVR[SDGs]SDG3asunaprevir; beclabuvir; boceprevir; daclatasvir; elbasvir; elbasvir plus grazoprevir; glecaprevir; glecaprevir plus pibrentasvir; grazoprevir; ledipasvir; ledipasvir plus sofosbuvir; ombitasvir; ombitasvir plus paritaprevir plus ritonavir; paritaprevir; pibrentasvir; ribavirin; simeprevir; sofosbuvir; telaprevir; velpatasvir; voxilaprevir; ABT-493; antivirus agent; benzimidazole derivative; benzofuran derivative; elbasvir-grazoprevir drug combination; imidazole derivative; pibrentasvir; quinoxaline derivative; sofosbuvir; sulfonamide; Article; clinical practice; disease classification; drug efficacy; drug safety; hemodialysis; hepatitis C; human; kidney failure; kidney graft; priority journal; sustained virologic response; chronic hepatitis C; chronic kidney failure; complication; drug combination; drug contraindication; genetics; genotype; Hepacivirus; practice guideline; Antiviral Agents; Benzimidazoles; Benzofurans; Contraindications, Drug; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Responsejournal article10.1007/s12072-018-9915-5305395172-s2.0-85058543693